Search

Your search keyword '"J. De Castro Carpeno"' showing total 71 results
Start Over Author "J. De Castro Carpeno"
71 results on '"J. De Castro Carpeno"'

1. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)

Author

B. Sierra-Rodero, C. Martínez-Toledo, M. Molina-Alejandre, V. Calvo, E. Nadal, B. Massuti Sureda, R. García Campelo, C. Gonzalez Ojea, A. Martinez-Marti, M. Domine Gomez, S. Ponce Aix, M.A. Insa Molla, J. De Castro Carpeno, M. Majem, I.C. Barneto Aranda, D. Rodriguez-Abreu, E. del Barco, M. Cobo Dols, M. Provencio Pulla, and A. Cruz-Bermudez

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2023

2. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain

Author

J. De Castro Carpeno, A Franceschetti, D Bell, Y Escobar Álvarez, and A Drago

Subjects
Cancer Research, medicine.medical_specialty, Consensus, Databases, Factual, Vomiting, Nausea, medicine.drug_class, medicine.medical_treatment, Antineoplastic Agents, Dexamethasone, Carboplatin, 03 medical and health sciences, chemistry.chemical_compound, MASCC/ESMO guidelines adherence, 0302 clinical medicine, Neurokinin-1 Receptor Antagonists, Internal medicine, medicine, Humans, Serotonin 5-HT3 Receptor Antagonists, Antiemetic, Anthracyclines, 030212 general & internal medicine, Cyclophosphamide, NK1RA-based regimens, Cisplatin, Chemotherapy, business.industry, Cancer, General Medicine, medicine.disease, Oncology, chemistry, Spain, Highly emetogenic chemotherapy, Health Care Surveys, 030220 oncology & carcinogenesis, Chemotherapy-induced nausea and vomiting, Antiemetics, Guideline Adherence, medicine.symptom, business, Research Article, medicine.drug
Abstract

Purpose Proper monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with antiemetics is crucial for cancer patients. This study aimed to evaluate the use of antiemetics for the treatment of highly emetogenic chemotherapy (HEC) including carboplatin in the real-world setting in Spain. Methods A representative panel of cancer specialists was asked to collect information about the antiemetic treatments provided to patients receiving chemotherapy. Records formed part of the Global Oncology Monitor© database (Ipsos Healthcare, London, UK). Chemotherapy data were extrapolated using Ipsos Healthcare’s projection methodology. Results A total of 73 experts were finally included. Data from 9519 patients, estimated to be representative of 202,084 patients, were collected. HEC (and carboplatin-based chemotherapy) was administered to 73,118 (36%) patients, cisplatin-based therapy being the most frequent treatment (n = 34,649, 47.38%). Neurokinin-1 receptor antagonists (NK1RAs) alone or in combination were used as prophylaxis for CINV in 14,762 (20%) patients, while the combination of NK1RA with 5-hydroxytryptamine-3 receptor antagonist (5-HT3RAs) and dexamethasone as recommended by the international guidelines was used in 5849 (8%) patients only. No antiemetic prophylaxis was administered to 8.46% of the patients receiving HEC (n = 6189). Physicians classified cisplatin-, anthracycline-cyclophosphamide (AC-), and carboplatin-based regimens as HEC in 63%, 22% and 4% of the cases, respectively. Conclusions The use of NK1RA-containing regimens for CINV prevention in patients treated with HEC was less than expected, suggesting poor adherence to international antiemetic guidelines.

Published
2021

6. 1010P Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics

Author

G. Ruiz de Garibay, B. Roch, P. Garrido Lopez, D. Isla, C. Aguado, A. Callejo Perez, R. Marse Fabregat, M.R. Garcia Campelo, A. Blasco Cordellat, J.M. Sanchez Torres, R. Bernabe Caro, O.J. Juan Vidal, J. De Castro Carpeno, F.F. Franco, I. Ramos Garcia, A. Gomez Rueda, E. Conde Gallego, S. Ponce Aix, L. Paz-Ares, and J. Zugazagoitia

Subjects
Oncology, Hematology
Published
2022

7. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

Author

M. Casarrubios, A. Cruz-Bermudez, B. Sierra-Rodero, C. Martinez, E. Nadal, M.A. Insa Molla, J. Mosquera Martinez, C. Gonzalez Ojea, M. Domine Gomez, M. Majem Tarruella, D. Rodriguez Abreu, A. Martinez-Marti, J. De Castro Carpeno, M. Cobo Dols, G. Lopez Vivanco, R. Bernabe Caro, N. Vinolas Segarra, I.C. Barneto Aranda, B. Massuti Sureda, and M. Provencio Pulla

Subjects
Oncology, Hematology
Published
2022

8. 1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain

Author

M.R. Garcia Campelo, M. Domine Gomez, J. De Castro Carpeno, A.L. Moreno Vega, S. Ponce Aix, E. Arriola, E. Carcereny Costa, M. Majem Tarruella, G. Huidobro Vence, E. Esteban Gonzalez, J. Fuentes Pradera, A.L.O. Ortega Granados, M. Guillot Morales, B. Massuti Sureda, L. Vila Martinez, A. Blasco Cordellat, C.A. Fajardo, L. Crama, N. Lerones Laborda, and M. Cobo Dols

Subjects
Oncology, Hematology
Published
2022

13. 1364TiP Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy

Author

J. De Castro Carpeno, A. Blasco Cordellat, Byoung Cheol Cho, A-L. Bauchet, A. Tomova, S. Bensfia, Jaquelline Germano de Oliveira, C. Aguado de la Rosa, T.M. Kim, L. Vilà, G. Dy, Dolores Isla, and C. Soufflet

Subjects
Antitumor activity, Chemotherapy, business.industry, medicine.medical_treatment, Hematology, Immunotherapy, medicine.disease, Ramucirumab, Oncology, Pharmacokinetics, Non squamous, Cancer research, medicine, Non small cell, Lung cancer, business
Published
2021

14. 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy

Author

M. Casarrubios, A. Cruz-Bermudez, B. Sierra-Rodero, E. Nadal, M.A. Insa Molla, M.R. Garcia Campelo, C. Garcia Benito, M. Domine Gomez, M. Majem Tarruella, D. Rodriguez-Abreu, A. Martinez, J. De Castro Carpeno, M. Cobo Dols, G. Lopez Vivanco, N. Vinolas Segarra, I.C. Barneto Aranda, S. Viteri, B. Massuti Sureda, and M. Provencio Pulla

Subjects
Oncology, Hematology
Published
2022

15. P48.04 IMfirst; Phase IIIB Safety Study of Atezolizumab Plus Chemotherapy in a Real World Population of Untreated ES-SCLC

Author

M. Domine Gomez, A. Moreno Vega, M. Cobo Dols, R. Garcia Campelo, L. Crama, E. Arriola Aperribay, P. Ruiz Gracia, M. Majem Tarruella, and J. De Castro Carpeno

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Chemotherapy, business.industry, Atezolizumab, medicine.medical_treatment, Internal medicine, Medicine, business
Published
2021

17. LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)

Author

Giovanni Luca Ceresoli, J. Baena Espinar, Matthew D. Hellmann, M.C. Garassino, Fred R. Hirsch, Leora Horn, Balazs Halmos, Li-Ching Huang, A. G. Rueda, Isabelle Monnet, Enriqueta Felip, J. De Castro Carpeno, M. Tiseo, Heather A. Wakelee, Valter Torri, U. Tapan, J. Rogado, Jennifer G. Whisenant, M. Majem Tarruella, and Solange Peters

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Oncology, Coronavirus disease 2019 (COVID-19), business.industry, Internal medicine, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Medicine, Hematology, Thoracic cancer, business, Article
Published
2020

18. Résultats à 5 ans des essais cliniques randomisés de phase III CheckMate (CM) 017/057 : nivolumab vs docétaxel dans le cancer bronchique non à petites cellules (CBNPC) avancé après un traitement antérieur

Author

Adam Pluzanski, M. Chiara Garassino, Joanna Wojcik-Tomaszewska, J. De Castro Carpeno, S. Marimuthu, Ang Li, E. Felip, M. Alonso Garcia, David M. Waterhouse, Neal Ready, Charles Butts, Everett E. Vokes, O. Aren Frontera, Hossein Borghaei, Manuel Domine, S.J. Antonia, Julie R. Brahmer, Oscar Arrieta, Marco Angelo Burgio, Fabrice Barlesi, David R. Spigel, Scott N. Gettinger, David E. Gerber, Bruno Coudert, L. Crinò, Laura Q.M. Chow, M. Wohlleber, W. Eberhardt, Rita Chiari, and Grzegorz Czyzewicz

Subjects
Pulmonary and Respiratory Medicine
Abstract

Introduction Historiquement, la survie des patients atteints de CBNPC avance etait mediocre, avec des taux a 5 ans Methodes Les patients (n = 854 ; CM 017/057 regroupes) atteints d’un CBNPC avance, avec un ECOG PS ≤ 1 et dont la maladie avait progresse pendant ou apres une premiere ligne de chimiotherapie ont ete randomises 1 :1 pour recevoir nivolumab 3 mg/kg toutes les 2 semaines ou docetaxel 75 mg/m2 toutes les 3 semaines jusqu’a progression ou toxicite inacceptable. La SG etait le critere principal d’evaluation pour les deux etudes. Resultats A 5 ans de suivi, 50 patients dans le bras nivolumab et 9 patients dans le bras docetaxel etaient en vie. Les caracteristiques initiales des survivants a 5 ans dans les deux bras etaient similaires a celles de la population globale et a celles des patients ayant survecu Conclusion Les CM 017 et CM 057 sont les premiers essais de phase III a rapporter les resultats a 5 ans d’un anti-PD1 dans le CBNPC avance prealablement traite et font etat d’une augmentation de plus de 4 fois des taux de SG a 5 ans avec nivolumab (13 %) par rapport au docetaxel (3 %). Le traitement par nivolumab reste bien tolere, sans nouveau signal de toxicite.

Published
2020

19. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC

Author

S. Marimuthu, Hossein Borghaei, Oscar Arrieta, Fabrice Barlesi, Marco Angelo Burgio, Rita Chiari, J. De Castro Carpeno, David R. Spigel, David M. Waterhouse, David E. Gerber, Grzegorz Czyzewicz, E. Felip, Everett E. Vokes, M. Lind, O. Aren Frontera, Bruno Coudert, Manuel Domine, Laura Q.M. Chow, M.C. Garassino, M. Wohlleber, Charles Butts, W. Eberhardt, L. Crinò, Anthony Li, M. Alonso Garcia, Adam Pluzanski, S.J. Antonia, Joanna Wojcik-Tomaszewska, Scott N. Gettinger, Julie R. Brahmer, and Neal Ready

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Checkmate, Docetaxel, Internal medicine, Medicine, Nivolumab, business, Previously treated, medicine.drug
Published
2020

21. 81P Predictive molecular parameters of pneumonitis development in stage IIIa NSCLC patients treated with neo-adjuvant chemo-immunotherapy from NADIM clinical trial

Author

Alberto Cruz-Bermúdez, Alex Martinez-Marti, J. De Castro Carpeno, M. Casarrubios, D. Rodriguez Abreu, Raquel Laza-Briviesca, Nuria Viñolas, A. Insa, I.C. Barneto Aranda, J. Casal Rubio, M. Martínez-Cutillas, Belén Sierra-Rodero, M.R. Garcia Campelo, M. Domine Gomez, M. Provencio, B. Massuti Sureda, M. Majem Tarruella, Ernest Nadal, E. Del Barco, and Y. Garitaonaindia

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Neo adjuvant, medicine.disease, Clinical trial, Stage IIIA NSCLC, Internal medicine, Medicine, business, Chemo immunotherapy, Pneumonitis
Published
2021

22. 115P Survival data from EMPOWER-Lung 4: Phase II study of cemiplimab plus ipilimumab in the second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC)

Author

Yvonne Summers, J. De Castro Carpeno, Hwa Ryeon Kim, P. Rietschel, S. Lee, M. Majem Tarruella, M. Cobo, Y. Xu, Byoung Yong Shim, C.A. Thomas, C-H. Chiu, I. Lowy, and Jeong Seon Ryu

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung, business.industry, Phases of clinical research, non-small cell lung cancer (NSCLC), Ipilimumab, medicine.disease, Survival data, Second line, medicine.anatomical_structure, Internal medicine, Medicine, business, medicine.drug
Published
2021

23. 1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)

Author

I. Lowy, C.A. Thomas, C-H. Chiu, M. Cobo, M. Majem Tarruella, P. Rietschel, H.R. Kim, Y. Xu, Jeong Seon Ryu, J. De Castro Carpeno, S. Lee, Yvonne Summers, and Byoung-Yong Shim

Subjects
Oncology, medicine.medical_specialty, Lung, Second line treatment, business.industry, non-small cell lung cancer (NSCLC), Ipilimumab, Hematology, medicine.disease, medicine.anatomical_structure, Internal medicine, Medicine, Open label, business, medicine.drug
Published
2020

25. 1275P Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group

Author

R. Blanco, Judith Dalmau, Javier Martinez-Picado, M. González Cao, Teresa Moran, M. Provencio Pulla, J. De Castro Carpeno, Ana Drozdowskyj, R. Rosell Costa, R. Bernabé, Bonaventura Clotet, Julia G. Prado, O.J. Juan Vidal, Julià Blanco, Javier Garcia-Corbacho, M.A. Molina-Vila, B. Massuti Sureda, and Andreas Meyerhans

Subjects
Oncology, medicine.medical_specialty, Durvalumab, business.industry, Human immunodeficiency virus (HIV), Phases of clinical research, Hematology, medicine.disease, medicine.disease_cause, Internal medicine, medicine, Lung cancer, business
Published
2020

26. Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database

Author

M. Domine Gomez, J. De Castro Carpeno, M.R. Garcia Campelo, M. Cobo Dols, P. Ruiz Gracia, and L. Crama

Subjects
0301 basic medicine, medicine.medical_specialty, Extensive Disease, business.industry, Seer database, Anova test, Hematology, Aggressive disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Family medicine, Long term survival, Medicine, In patient, Non small cell, business, Stage iv
Abstract

Background SCLC represents the subtype with worst survival among lung cancer patients. Despite initial good response to platinum based chemotherapy in extensive disease, these patients relapse fast with an unfortunate prognosis. The majority of overall survival (OS) data reported show a median between 8-10 months (mo) based on randomized clinical trials and meta-analysis. Methods The aim of this study is to analyze survival outcomes in IV-SCLC patients in real clinical practice based on SEER database and identify which patients have worse outcomes. We selected all patients with SCLC from SEER database diagnosed between 2010-2015. Bivariate analysis was used by chi-square determination for the association of binary qualitative variables and the ANOVA test to compare 2 or more variables. A multivariate analysis using Cox regression was performed, measuring the effect by Hazard Ratios (HR) and their 95% confidence intervals to determine the impact of these prognostic factors on OS. AJCC 7 was used for TNM staging. Results We included 26,221 patients with SCLC. Men: 50.7%. 55.7% patients were ≥ 65 years old. Median age: 67 years old. 82% were caucasian. 70.84% were stage IV. These patients showed a median OS (mOS) of 6mo (5.83-6.17). 45.37% of them had liver metastasis (mets), bone: 33.41%, brain: 23.86%, lung: 19.47% and other mets sites: 16.88%. Median OS in patients with liver mets, bone, brain and lung were 4 (3.79-4.21), 6 (5.74-6.26), 6 (5.71-6.29) and 5 mo (4.63-5.37) respectively. Patients involving both lung and liver mets with 3 or more mets sites showed the worst survival with 3 (1.99-4.00) and 4 (3.11-4.89) mo of mOS respectively. The percentage of patients alive at 6, 12, 24 y 60 mo were 47.70%, 21.64%, 5.91% and 1.61% respectively. Conclusion This real world data analysis reflects that the chance of having long term survivors in SCLC is very low and that mOS has not been improved over the last years. The introduction of new therapies such as immune checkpoints opens a new opportunity for long term survival and better outcomes in this aggressive disease. Legal entity responsible for the study Roche Farma S.A. Funding Roche Farma S.A. Disclosure J. de Castro Carpeno: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZ; Advisory / Consultancy: Pfizer; Advisory / Consultancy: PharmaMar; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Advisory / Consultancy: Tesaro. M. Cobo Dols: Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZ; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Boehringer. M. Domine Gomez: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZ; Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Abbvie; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Boehringer. P. Ruiz Gracia: Full / Part-time employment: Roche. L. Crama: Full / Part-time employment: Roche. M.R. Garcia Campelo: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZ; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: PharmaMar; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Abbvie; Advisory / Consultancy, Speaker Bureau / Expert testimony: GSK; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Boehringer.

Published
2019

27. P2.01-81 Predictive Factors of Survival in Patients Treated with Nintedanib: A Multicenter Retrospective Spanish Study

Author

S. Martínez Recio, Y. Lage Alfranca, X. Mielgo, E. Martinez Moreno, Carlos Aguado, J. De Castro Carpeno, M. Antoñanzas, A. Garcia Rueda, L.E. Chara, Patricia Cruz, Maria Eugenia Olmedo, L. Gutiérrez Sainz, M. Sotelo, L. Cabezón, and A. Velastegui

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, chemistry.chemical_compound, Oncology, chemistry, business.industry, Internal medicine, medicine, Nintedanib, In patient, business
Published
2019

28. P2.10-02 Smoking Habit in Lung Cancer in Spain

Author

Carlos Camps, Ana Ortega, E. Del Barco, A. Padilla, Joaquim Bosch-Barrera, F. Franco, J. De Castro Carpeno, Manuel Domine, Jose-Luis Gonzalez-Larriba, R. Garcia Campelo, Juana Oramas, Gretel Benítez, M. Guirado, R. Lopez Castro, Montserrat Domenech, R. Blanco, Enric Carcereny, S. Cerezo, R. Bernabé, David Aguiar, Delvys Rodriguez-Abreu, G. Huidobro, M. Provencio, M.A. Sala, B. Massuti, E. Cuadrado Albite, and R. de las Peñas

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Oncology, Smoking habit, business.industry, Internal medicine, medicine, Lung cancer, medicine.disease, business
Published
2019

29. OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

Author

Oscar Arrieta, Charles Butts, E. Felip, Bruno Coudert, Everett E. Vokes, Neal Ready, Manuel Domine, Fabrice Barlesi, Adam Pluzanski, David M. Waterhouse, S.J. Antonia, S. Marimuthu, M. Alonso Garcia, Ang Li, Julie R. Brahmer, Marco Angelo Burgio, Hossein Borghaei, Scott N. Gettinger, O. Aren Frontera, David R. Spigel, J. De Castro Carpeno, David E. Gerber, Joanna Wojcik-Tomaszewska, M.C. Garassino, L. Crinò, Laura Q.M. Chow, M. Wohlleber, W. Eberhardt, Rita Chiari, and Grzegorz Czyzewicz

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Docetaxel, business.industry, Internal medicine, medicine, Checkmate, Nivolumab, Previously treated, business, medicine.drug
Published
2019

30. EP1.06-11 Advanced Malignant Pleural Mesothelioma: A Single Institution Experience

Author

J. De Castro Carpeno, J. Villamayor, S. Martínez Recio, L. Gutiérrez Sainz, D. Viñal, Isabel Esteban, D. Sanchez Cabrero, F. Arias Lotto, Pedro Mateos Cruz, and Oliver Higuera

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Oncology, business.industry, Pleural mesothelioma, General surgery, medicine, Single institution, business
Published
2019

31. EP1.06-02 Association of Inflammatory Biomarkers with Overall Survival in Patients with Advanced Malignant Pleural Mesothelioma

Author

J. Villamayor, L. Gutiérrez Sainz, Isabel Esteban, Oliver Higuera, D. Sanchez Cabrero, F. Arias Lotto, Pedro Mateos Cruz, S. Martínez Recio, J. De Castro Carpeno, and D. Viñal

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Pleural mesothelioma, Internal medicine, medicine, Overall survival, In patient, business, Inflammatory biomarkers
Published
2019

32. EP1.18-28 Neoadjuvant Therapy Among Patients Undergoing Resection for Non-Small-Cell Lung Cancer: A Single Institution Experience

Author

J. De Castro Carpeno, Oliver Higuera, S. Martínez Recio, L. Gutiérrez Sainz, D. Sanchez Cabrero, Isabel Esteban, D. Viñal, F. Arias Lotto, J. Villamayor, and Patricia Cruz

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, medicine.medical_treatment, medicine.disease, Resection, Oncology, Medicine, Non small cell, Radiology, Single institution, business, Lung cancer, Neoadjuvant therapy
Published
2019

33. P2.01-55 Immunotherapy First or After Nintedanib?: A Spanish Experience

Author

J. De Castro Carpeno, A. Velastegui, L. Cabezón, Maria Eugenia Olmedo, L. Gutiérrez Sainz, S. Martínez Recio, M. Antoñanzas, Cristina Aguado, X. Mielgo, Y. Lage Alfranca, Pedro Mateos Cruz, M. Sotelo, E. Martinez Moreno, A. Garcia Rueda, L.E. Chara, and I. Gómez-Barreda

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, chemistry.chemical_compound, chemistry, business.industry, Internal medicine, medicine.medical_treatment, medicine, Nintedanib, Immunotherapy, business
Published
2019

34. Efficacy and safety results from AvaALL: an open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo)

Author

Frank Griesinger, Ashis Das-Gupta, J. De Castro Carpeno, AM Dingemans, Vlatka Smoljanovic, Cesare Gridelli, Margarita Donica, Yuichiro Ohe, Francesco Grossi, Corey J. Langer, Kostas N. Syrigos, Nick Thatcher, and Jaafar Bennouna

Subjects
Pulmonary and Respiratory Medicine, Oncology, Chemotherapy, medicine.medical_specialty, Standard of care, Bevacizumab, business.industry, First line, medicine.medical_treatment, non-small cell lung cancer (NSCLC), medicine.disease, Internal medicine, Medicine, In patient, Open label, business, medicine.drug
Published
2018

35. BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial

Author

Emilio Esteban, M.D. Isla Casado, I.C. Barneto Aranda, Angel Artal-Cortes, Ma.Teresa Alvarez y Muñoz, José Sánchez-Payá, J.M. Sanchez Torres, Jose-Luis Gonzalez-Larriba, M. Provencio, D. Rodriguez Abreu, J. De Castro Carpeno, Rosa Rosell, E. Pereira, M.T. Moran Bueno, B. Massuti Sureda, L. Iglesias, G. López Vivanco, M. Cobo Dols, R. López, and R. de las Penas Bataller

Subjects
Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, Cancer, Hematology, medicine.disease, Chemotherapy regimen, Gastroenterology, Clinical trial, medicine.anatomical_structure, Oncology, Docetaxel, Internal medicine, Relative risk, medicine, business, Lung cancer, Lymph node, medicine.drug
Abstract

Background Post-operative platinum-based chemotherapy is the standard of care for resected NSCLC with nodal involvement. Expression of genes involved in DNA repair may have a prognostic role for the outcome. BRCA1 plays an important role in DNA repair pathways and could have a prognostic impact in this setting. The SCAT trial results found that for low BRCA1 levels subgroup Cis-Gem was superior to Cis-Doc and in high BRCA1 subgroup docetaxel single agent without platinum achieved similar survival to Cis-Doc. Risk of recurrence analysis according BRCA-1 levels has been performed. Methods From Jun/2007 to May/2013 591 patients were screened and 500 were included, 108 in the control arm treated with Cis-Docetaxel and 392 in the experimental arms treated with Cis-Gem, Cis-Doc or docetaxel alone according to terciles of BRCA1 expression level. With a cut-off September 30th 2018 and a median follow-up of 60 months, recurrence patterns were analysed for the whole group according BRCA1 levels in tumor tissue and comparison were made for risk of recurrence, single/multiple recurrence, thoracic/extrathoracic and metastatic sites (liver, bone, brain). Results Cumulative recurrence was evaluable in 232/456 patients (50.8%), 182/354 patients treated in the experimental arm and in 50/102 patients treated in the control arm (RR 1.04; 0.83-1.30) (p = 0.672). The majority of recurrences 159/232 (68.5%) were single site intrathoracic recurrences in 121/232 (52%) while 111/232 were extrathoracic (47.8%). Overall recurrence was 56.5% (113/200 p) for low tercile BRCA1 vs 48.8% (63/129) for intermediate tercile vs 44% (56/127) for high tercile (p = 0.025). No differences were seen between tercile groups for single site (p = 0.35), multiple site (p = 0.26), intrathoracic (p = 0.36), or extrathoracic (p = 0.38). More frequent distant metastatic sites were: bone (42 patients), brain (38 patients) and liver (11 patients). RIsk reduction was seen for brain metastases in patients with higher tercile BRCA1 (p = 0.003). Conclusions For NSCLC resected patients with lymph node involvement risk of recurrence remains high with a cumulative rate > 50%. Relative risk of recurrence was lower for tumors with higher BRCA1 levels. Distant metastases were seen in 47.8% of patients. Brain metastases risk was significant lower for patients with low BRCA1 expression. BRCA1 levels acts as a prognostic factor in early stages NSCLC. Clinical trial identification EudraCT: 2007-000067-15; NCT 00478699. Legal entity responsible for the study Spanish Lung Cancer Group - Grupo Espanol Cancer de Pulmon. Funding Sanofi Aventis. Disclosure All authors have declared no conflicts of interest.

Published
2019

36. Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies

Author

I. Esteban Rodriguez, Carlos Rodriguez-Antolin, Rocío Rosas-Alonso, Inmaculada Ibáñez de Cáceres, P. Cruz Castellanos, and J. De Castro Carpeno

Subjects
Genetics, business.industry, Wild type, Hematology, Gene mutation, Genome, DNA sequencing, Oncology, CDKN2A, Medicine, Copy-number variation, business, Allele frequency, Gene
Abstract

Background The next-generation sequencing (NGS) technology has increased the number of genes and types of genomic alterations detectable by a high-throughput assay and has become an essential part of clinical decision-making. We aimed to verify the analytical specifications of TruSight™ Tumor 170 (TST170, Illumina Inc.) panel for detecting 5% variant allele frequency (VAF) and reliable amplifications (copy number variants, CNVs) for ensuring high quality of sequencing results. Methods We use well-characterized human cancer cell lines mixtures with known specific gene mutations to evaluate the specifications given by TST170 and defined thresholds for each type of genomic alterations intended to detect. We performed the following mixing studies by using the lung adenocarcinoma cell lines H1975 and H1299 to acquired proportions: 100%, 33%, 10% and 2% H1975. H1975 harbors EGFR p.Thr790Met (c.2369C>T), p.Leu858Arg (c.2573T>G), TP53 p.Arg273His (c.818G>A), CDKN2A p.Glu69Ter (c.205G>T) and PIK3CA p.Gly118Asp (c.353G>A). H1299 harbors an EGFR, CDKN2A, PIK3CA wild type and a homozygous partial deletion of the TP53 gene. We extracted DNA and performed NGS TST170 analysis with each diluted sample. Results When we calculated the correlation between the expected and observed VAFs by linear regression analysis, the coefficient of determination was 0.99 in hotspot NSCLC genes. This result further supports the reliability of this system for variant identification. Mutations with a low VAF ( 5% VAF were detected without exception. In the CNV analysis, the number of copies seen in the undiluted cell line (100% H1975) were found in all 33% dilution cases, in one third of the 10% dilution cases and in no case in the 2% dilution, independently of undiluted cell line fold changes. Conclusions Our analytical verification determines the ability of TST170 pipeline to detect 5% VAF with high confidence and CNVs in samples of tumor purity at 33% or more. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

Published
2019

38. EP1.12-29 Retrospective Study About Small Cell Lung Cancer: Our Experience in a Spanish Hospital

Author

A. Pertejo, J. Villamayor, J.L. Torres, J. Ramón, Oliver Higuera, S. Martinez, J. De Castro Carpeno, D. Sanchez Cabrero, L. Gutierrez, Isabel Esteban, P. Perez, Pedro Mateos Cruz, and D. Viñal

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Retrospective cohort study, Non small cell, business
Published
2019

39. MA22.05 Assessment of Gender Differences in the Psychosocial and Economic Impact on Patients with Stage IV Non-Small Cell Lung Cancer

Author

J.L. González Larriba, Pilar Lianes, J. Coves, E. Felip, A. Blasco, Margarita Majem, Oscar Juan, Manuel Domine, R. Garcias De Las Peñas, R. Garcia Campelo, Silvia Catot, M. Provencio, J. De Castro Carpeno, Angel Artal, Nuria Viñolas, Enric Carcereny, Dolores Isla, Pilar Garrido, Jordi Remon, J. Terrassa, and J. J. Garcia

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Economic impact analysis, business, Psychosocial, Stage IV non-small cell lung cancer
Published
2019

40. P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

Author

Nuria Viñolas, M. Casarrubios, Alberto Cruz-Bermúdez, E. Nadal, Guillermo Lopez-Vivanco, E. Del Barco, M. Cobo, Delvys Rodriguez-Abreu, M. Provencio, Bartomeu Massuti, A. Insa, Isidoro Barneto, Manuel Domine, N. De Dios Alvarez, R. Bernabé, V. Calvo De Juan, R. Garcia Campelo, Raquel Laza-Briviesca, Margarita Majem, Santiago Viteri, Alex Martinez-Marti, and J. De Castro Carpeno

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Stage IIIA NSCLC, Internal medicine, Medicine, Pathological response, Neo adjuvant, business, Chemo immunotherapy
Published
2019

41. P2.01-98 Neutrophil-Platelet Score (NPS), a Predictive Systemic Inflammation Score for Pembrolizumab in First Line of Advanced NSCLC Patients

Author

E. Pérez Fernández, P. Dhimes, Pedro Mateos Cruz, Luis Cabezon-Gutierrez, S. Custodio, M. Sotelo, R. Lopez Castro, José Antonio Rubio, C. Olier, M. Antoñanzas, María Sereno, Antonio López, Cristina Aguado, J. De Castro Carpeno, A. Velastegui, Sandra Falagan, I. Nalda Ariza, X. Mielgo Rubio, Jazmina Núñez, and L.E. Chara

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, First line, Internal medicine, medicine, Platelet, Pembrolizumab, medicine.symptom, business, Systemic inflammation
Published
2019

42. EP1.12-20 Retrospective Study About the Impact of Metastatic Site in Small Cell Lung Cancer

Author

Isabel Esteban, A. Pertejo, D. Viñal, P. Perez, J. Villamayor, J. De Castro Carpeno, S. Martinez, D. Sanchez Cabrero, L. Gutierrez, J.L. Torres, J. Ramón, Oliver Higuera, and Pedro Mateos Cruz

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Retrospective cohort study, Non small cell, business
Published
2019

43. EP1.06-09 Mesothelial Tumors Registry in Spain: A Retrospective Multicenter Study

Author

L. Gutiérrez Sainz, S. Martínez Recio, J. De Castro Carpeno, I. Nalda Ariza, A. Velastegui, X. Mielgo, Pedro Mateos Cruz, Y. Lage Alfranca, E. Martinez Moreno, V. Sotelo Peña, and L.E. Chara

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Oncology, Multicenter study, business.industry, Internal medicine, medicine, business
Published
2019

45. EP1.12-26 Retrospective Study About the Impact of Brain Metastases and Cranial Irradiation in Small Cell Lung Cancer

Author

S. Martinez, D. Sanchez Cabrero, J. De Castro Carpeno, P. Perez, L. Gutierrez, J.L. Torres, Isabel Esteban, J. Ramón, D. Viñal, Pedro Mateos Cruz, Oliver Higuera, A. Pertejo, and J. Villamayor

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Oncology, Cranial Irradiation, business.industry, Medicine, Retrospective cohort study, Radiology, Non small cell, business
Published
2019

46. OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses

Author

Åslaug Helland, Kerstin Trunzer, Juergen Wolf, A. Cardona, Frank Griesinger, Vlatka Smoljanovic, Maria Rita Migliorino, In-Joon Oh, Thorsten Ruf, Julien Mazieres, J. De Castro Carpeno, Rafal Dziadziuszko, M. Chlistalla, and Silvia Novello

Subjects
Pulmonary and Respiratory Medicine, Alectinib, Oncology, business.industry, Genomic sequencing, Cancer research, Medicine, business
Published
2019

47. P2.03-33 ctDNA Levels Significantly Predicts Survival in NSCLC Patients with an EGFR Activating Mutation

Author

Carlos Camps, Manuel Domine, C. García Girón, Juana Oramas, Jose Miguel Sanchez, X. Mielgo Rubio, M. Sotelo, J. Coves, M. Provencio, R. Serna Blasco, M.A. Sala, E. Sánchez Herrero, L.E. Chara, E. Jantus, F. Franco, J. Balsalobre, Berta Hernandez, A. Padilla, Alfredo Sanchez-Hernandez, J. De Castro Carpeno, R. Blanco, Ana Laura Ortega, Joaquim Bosch-Barrera, M. Barquín Del Romo, María Sereno, M. Auglite, V. Calvo De Juan, and Alejandro Romero

Subjects
Pulmonary and Respiratory Medicine, Oncology, business.industry, Cancer research, Medicine, EGFR Activating Mutation, business
Published
2019

48. OA13.05 NADIM Study: Updated Clinical Research and Outcomes

Author

Santiago Viteri, Alex Martinez-Marti, J. De Castro Carpeno, J. Casal, Guillermo Lopez-Vivanco, A. Insa, Nuria Viñolas, Manuel Domine, Isidoro Barneto, R. Bernabé, Margarita Majem, Delvys Rodriguez-Abreu, P. Martin Martorell, Maria Jove, M. Provencio, E. Del Barco, R. Garcia Campelo, M. Cobo, Bartomeu Massuti, V. Calvo De Juan, and E. Nadal

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Clinical research, Oncology, business.industry, medicine, Medical physics, business
Published
2019

49. P2.01-10 Real Clinical Practice Study to Evaluate 2 Line Treatment Based on Comprenhensive Genomic Profiling in NSCLC. LungONE Study

Author

A. Calles Blanco, E. Felip, R. Garcia Campelo, Alfredo Paredes, J. Terrassa, R. Bernabé, J. De Castro Carpeno, J. Campillo, Oscar Juan, R. Lopez Castro, L. García-Palacios, David Aguiar, Isidoro Barneto, and Federico Rojo

Subjects
Pulmonary and Respiratory Medicine, Clinical Practice, Genomic profiling, Oncology, business.industry, Medicine, Computational biology, Line (text file), business
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results